Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2015
[A clinical-electroneuromyographic study of the efficacy of ipidacrine in patients with mononeuropathies].
Контролируемое клиническое исследованиеАннотация на английскомСтатьяНазвание и аннотация: Оригинал на русском
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Avakyan G N, Avakyan G G
Аннотация
OBJECTIVE: To evaluate the efficacy and tolerability of axamon (ipidacrine) therapy in patients with focal neuropathies--mononeuropathies.
MATERIAL AND METHODS: We examined 35 patients, aged 18 years and older, with focal neuropathies (tunnel syndromes, radiculopathies). In the main group (n=20) axamon (ipidacrine) was prescribed in addition to the basic (standard) therapy (group B vitamins, lipoic acid) during 6 week, in the control group (n=15) patients remained only on the basic (standard) treatment.
RESULTS: In the main group positive clinical changes were accompanied by the more significant positive electroneuromyographic (ENMG) dynamics as compared to the control group (the increased amplitude of M-response in the muscles of the hand and feet; increased nerve conduction velocity in the peripheral nerves as a manifestation of remyelination activity, and others).
CONCLUSION: The obtained clinical and ENMG data indicate that axamon (ipidacrine) is a unique cholinesterase inhibitor with conduction action primarily targeting on efferent (motor) fibers of the peripheral nerves.
MATERIAL AND METHODS: We examined 35 patients, aged 18 years and older, with focal neuropathies (tunnel syndromes, radiculopathies). In the main group (n=20) axamon (ipidacrine) was prescribed in addition to the basic (standard) therapy (group B vitamins, lipoic acid) during 6 week, in the control group (n=15) patients remained only on the basic (standard) treatment.
RESULTS: In the main group positive clinical changes were accompanied by the more significant positive electroneuromyographic (ENMG) dynamics as compared to the control group (the increased amplitude of M-response in the muscles of the hand and feet; increased nerve conduction velocity in the peripheral nerves as a manifestation of remyelination activity, and others).
CONCLUSION: The obtained clinical and ENMG data indicate that axamon (ipidacrine) is a unique cholinesterase inhibitor with conduction action primarily targeting on efferent (motor) fibers of the peripheral nerves.